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The Composition of Ehrlichs Salvarsan:
Resolution of a Century-Old Debate**
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In 1910, Ehrlich introduced the compound 3-amino-4-
hydroxyphenylarsenic(i) (salvarsan, arsphenamine, or Ehr-
lich 606) as a remedy for syphilis, a disease caused by the
spirochaete bacterium Treponema pallidum. His methodical
search for a specific curative for an identified disease can be
regarded as the introduction of targeted chemotherapy.
Despite its long history and importance, the actual
structure of salvarsan is still debated.[1, 2] Ehrlich synthesized
the compound by the reaction of 3-nitro-4-hydroxyphenyl-
arsonic acid with dithionite.[3] This simultaneously reduced
the NO2 group to NH2 and As
V to AsI to give a material of
formula 3-H2N-4-HOC6H3As (Scheme 1). The product was
isolated as the hydrated hydrochloride salt of formula 3-H2N-
4-HOC6H3As·HCl·H2O. This synthesis was not always repro-
ducible, and inevitably gave rise to sulfur-containing impur-
ities, which may have accounted for the variable toxicity of
different batches of salvarsan.[5] A two-step process that
involved initial reduction of the NO2 group by sodium
dithionite followed by reduction of AsV with hypophos-
phorous acid was subsequently shown by Christiansen to lead
to sulfur-free material (Scheme 1).[4]
By analogy with azo compounds, Ehrlich assigned struc-
ture 1 to the free base of salvarsan. Although As=As bonds
are now known to be found only in sterically crowded
molecules,[6] the As=As form is repeatedly cited, with text-
books and reviews still giving structure 1.[1, 2] Various sugges-
tions for the true structure of salvarsan have been proposed,
including large polycyclic molecules[7] and polymers,[8] but
lack strong supporting data.
We now report the first definitive evidence for the
composition of salvarsan based on electrospray ionization
mass spectrometric data. Salvarsan was synthesized by using a
modification of the two-step synthesis first described by
Christiansen.[4] The compound was isolated as the hydrochlo-
ride, giving consistent yields of a pale-yellow material that
was analyzed as the monohydrate, corresponding exactly to
Ehrlichs original reports.[9] We also isolated the mixed
H2PO2
/H2PO3
 salt form (31P NMR spectroscopic data) by
direct precipitation from the reaction mixture.
1H and 13C NMR spectroscopic data were recorded for
salvarsan, but were not particularly useful for structural
assignment; ESI MS proved much more practical for this
purpose. A typical spectrum is shown in Figure 1. Although
there are many peaks, they can be readily assigned. Three
clear series can be identified (Table 1). The first of these is the
major one and consists of [(RAs)n+H]
+ peaks (R= 3-H2N-4-
HOC6H3) for n= 3–8. Peaks corresponding to n= 3 and n= 5
are clearly dominant in this series. A lesser series comprises
ions generated by loss of R from (RAs)n, that is, [Rn1Asn]
+
for n= 4–8. There are also minor peaks, which can be assigned
to species [(RAs)n+O+H]
+ arising from mild oxidation,
presumably through the insertion of an oxygen atom into the
Asn ring. There is a significant peak ([R2As]
+) which connotes
a fragmentation product of the cyclic polyarsines (see below).
Peaks corresponding to [RAs(OH)2+H]
+ and [RAs(OH)]+
arise from complete oxidative cleavage of As–As bonds.
The small peak at m/z 459 is a doubly charged ion (as
determined by the spacing in the high-resolution isotope
Scheme 1. Two routes to salvarsan (1). The initial route of Ehrlich and
Bertheim involves simultaneous reduction of the nitro group and AsV
(top arrow).[3] Christiansen’s two-step process of sequential reductions
is shown below. [4]
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pattern) and can be attributed to [(RAs)5+ 2H]
2+. Similarly,
there is a small overlapping contribution to the [(RAs)3+H]
+
peak at m/z 550 from doubly protonated [(RAs)6+ 2H]
2+
ions. There were no features in any of the mass spectra of the
type expected for higher-molecular-mass polymeric com-
pounds.
All the evidence indicates that salvarsan in solution
consists of cyclic species (RAs)n, with n= 3 (2) and n= 5 (3) as
the preferred sizes. We are confident that the ESI MS data
provide an accurate profile of the components of salvarsan in
solution, and that the species observed are not artifacts
generated in the mass spectrometer, for the following
reasons:
1) In many other areas it has been demonstrated that
ESI MS provides an accurate guide to solution speciation,
as the chemical ionization process is mild and does not
lead to significant fragmentation.[10] Ions present in
solution are transferred directly into the source. This is
why ESI is so much more informative than EI, FAB, or
MALDI in speciation studies.
2) The overall ESI MS profile does not change significantly
with varying skimmer cone voltage (20–100 V), with
varying pH, or with the different electrospray desolvation
mechanisms of the two different instruments used. If the
smaller rings were fragmentation products of larger
molecules, then the distribution of peaks would change
markedly under the different conditions. Furthermore,
when fragmentation of the specific rings was deliberately
induced in MS/MS experiments, the observed processes
involved elimination of R, R2As, and R3As fragments,
with no sign at all of conversion from larger into smaller
rings.
Whereas the ESI MS results are believed to give a true
qualitative reflection of the composition of salvarsan, quanti-
tative allocation to different ring sizes is less certain, as the ion
signal reflects ease of chemical ionization as well as relative
abundance.[10] However, each molecule in the series is chemi-
cally ionized (protonated) on the same type of NH2 group.
Therefore, a moderate correlation between signal intensity
and the amount present should exist. Certainly it appears that
(RAs)3 and (RAs)5 are the predominant molecules in the
mixture, with significant (RAs)4 and (RAs)6 present, and only
minor representation from larger ring sizes.
It is pertinent to ask why elucidation of the structure of
salvarsan has proved so difficult, as it has been established
that other organoarsenic(i) compounds such as (PhAs)n and
(MeAs)n can form rings (n= 5 and 6 for (PhAs)n, and n= 5
together with a polymeric ladder form for (MeAs)n).
[1] This is
a result of its resilient physical features—the material is a
mixture of compounds; it does not crystallize in a form
suitable for X-ray crystallographic analysis; it is not volatile,
so it cannot be examined by traditional mass spectrometric
methods; it is readily oxidized in solution (particularly at
neutral or higher pH values[11]) ; and it has strong hydrogen
bonding functional groups, which will complicate cryoscopic
mass measurements (salvarsan forms gels in aqueous solu-
tions at critical concentrations and pH values[4,12]).
We have attempted to separate salvarsan into its constit-
uent ring species with HPLC experiments. However, these
Figure 1. The ESI mass spectrum of salvarsan in H2O. Ions derived
from the different cycloarsines, (RAs)n, are indicated as values of n.
Assignment of other ions is given in Table 1.
Table 1: ESI mass spectral data for an aqueous solution of salvarsan.
m/z Irel [%] Assignment
[a]
1465 2 [(RAs)8+H]
+
1356 2 [(RAs)8R]+
1282 4 [(RAs)7+H]
+
1173 2 [(RAs)7R]+
1115 3 [(RAs)6O+H]
+
1099 18 [(RAs)6+H]
+
990 3 [(RAs)6R]+
932 5 [(RAs)5O+H]
+
916 90 [(RAs)5+H]
+
807 10 [(RAs)5R]+
749 5 [(RAs)4O+H]
+
733 43 [(RAs)4+H]
+
624 10 [(RAs)4R]+
550 100 [(RAs)3+H]
+
458.5 30 [(RAs)6+2H]
2+
291 61 [R2As]
+
218 50 [RAs(OH)2+H]
+
200 25 [RAs(OH)]+
[a] R=3-NH2-4-HOC6H3-; see Figure 1
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have so far been unsuccessful, presumably because of the high
reactivity and hydrogen bonding properties of the compound.
The (RAs)n rings formed by salvarsan are of interest,
especially the trimer, as an As3 ring does not seem to have
been confirmed before, although examples of both (RP)3 and
(RSb)3 are known.
[13] It is striking that the trimer and
pentamer appear to be the main forms when R= 4-hydroxy-
3-aminophenyl, whereas the hexamer and pentamer are the
only characterized examples for R= phenyl.[1, 7] (We note that
West and co-workers found a peak corresponding to
[(PhAs)3]
+ in the EI mass spectrum of (PhAs)n, but concluded
it to be a fragmentation ion rather than a true component of
the mixture.[14])
It has been accepted that salvarsan in the clinically
administered form differs from the active form in vivo.
Oxidation is needed to activate the compound.[15] This was
earlier assumed to give rise to what was originally formulated
as the oxide (RAs=O), but is undoubtedly RAs(OH)2 or a
condensation product thereof.[12] In essence, salvarsan (RAs)n
appears to serve as a slow-release source of RAs(OH)2. This
oxidation process was confirmed by our ESI MS results. Peaks
at m/z 218 and 200 can be assigned to [RAs(OH)2+H]
+ and
[RAs(OH)]+, respectively (Figure 1). As the sample was
exposed to air, these signals increased in intensity at the
expense of those from the various [(RAs)n+H]
+ species, until
after a few hours they completely dominated the spectrum.
In conclusion, we have demonstrated for the first time that
salvarsan consists of small rings (RAs)n, particularly 2 and 3,
rather than the commonly written form 1. Although this
assignment is based mainly on ESI mass spectrometry of the
mixture because the properties of the compound have so far
precluded separation into components, we are confident that
this work has provided an accurate description of the
dominant structures of salvarsan.
Experimental Section
ESI mass spectra were recorded on VG Platform and Finnegan LCQ
mass spectrometers. For the former, the compounds were dissolved in
the appropriate solvent and injected through a Rheodyne injector
equipped with a 10-mL sample loop. A flow rate of 0.02 mLmin1 and
a source temperature of 60 8Cwas used. Nitrogen was used as both the
nebulizing and drying gas. For the LCQ instrument, the sample was
directly injected at 5 mLmin1 with a syringe pump. The capillary
temperature was set at 100 8C. Nitrogen was used as the drying gas,
and argon for collisionally induced fragmentation. NMR spectro-
scopic data were recorded with a Bruker Avance 300 spectrometer. 3-
Nitro-4-hydroxyphenylarsonic acid (roxarsone) was purchased from
Aldrich.
Preparation of 3-amino-4-hydroxyphenylarsonic acid (adapted
from the method of Fargher[16]): 3-Nitro-4-hydroxyphenylarsonic acid
(13.1 g, 0.05 mol) was dissolved in a solution of aqueous NaOH (1m,
100 mL) and cooled to 0 8C in an ice/salt bath. Sodium dithionite
(Na2S2O4) (30.25 g) was added in one portion with vigorous stirring.
The solution effervesced. As soon as the color changed from orange
to pale yellow, concentrated aqueous HCl (12 mL) was added. This
mixture was held at < 0 8C until all frothing ceased and the product
precipitated from solution. The precipitate was filtered and washed
twice with ice-cold water to give crude 3-amino-4-hydroxyphenyl-
arsonic acid (6.50 g, 56%) as a cream-colored solid. This was dried
under vacuum for 24 h.
Purification of 3-amino-4-hydroxyphenylarsonic acid (adapted
from the method of Christiansen[4]): The crude product (6.0 g)
obtained above was dissolved in dilute aqueous HCl (H2O (25 mL),
concd HCl (2 mL)), and the solution was stirred with decolorizing
charcoal for 15 min. The mixture was filtered, and a solution of
sodium acetate (25%) was added to the filtrate until the solution was
no longer acidic to Congo Red. The solution was cooled to 4 8C for
20 min. The resulting precipitate was collected by filtration and dried
under vacuum to yield 3-amino-4-hydroxyphenylarsonic acid (4.7 g,
78%) as an off-white microcrystalline solid. 1H NMR ([D6]DMSO):
d= 6.97, 6.81 ppm; 13C NMR: d= 114.5, 115.0, 119.0, 122.6, 137.8,
148.3 ppm; ESI MS (H2O): positive ion m/z 234 [M+H]
+, 449
[2MH2O+H]+, 664 [3M2H2O+H]+; negative ion m/z 232
[MH] , 465 [2MH] , 698 [3MH] . Elemental analysis calcd
for C6H8AsNO4: C 30.90, H 3.43, N 6.01%; found: C 30.76, H 3.41,
N 6.32%.
Preparation of salvarsan (3-amino-4-hydroxyphenylarsenic(i))
(adapted from the method of Christiansen[4]): All solvents and
solutions were degassed and the reaction was carried out under
nitrogen. 3-Amino-4-hydroxyphenylarsonic acid (2.3 g, 0.01 mol) was
dissolved in a solution of hypophosphorous acid (14 mL, 50%) in
water (73 mL). An aqueous solution of KI (1 mL, 3%) was added,
and the solution was heated gradually to 55 8C and held between 55
and 608C for 90 min. The mixture was cooled to 10 8C and poured
with vigorous stirring into a cold mixture of HCl/H2O (1:1, 164 mL).
Salvarsan precipitated as a pale yellow gelatinous solid, which was
collected and dried under vacuum as the hydrochloride. Elemental
analysis calcd for C6H6AsNO·HCl·H2O: C 30.37, H 3.80, N 5.91%;
found: C 30.66, H 3.70, N 5.62%. Alternatively, ethanol was added to
the cooled reaction mixture after the heating step with vigorous
stirring, until a precipitate formed. The solid was collected and dried
as above, and was characterized as a mixed hypophosphite/phosphite
salt of 3-amino-4-hydroxyphenylarsenic(i). 31P NMR (D2O): d=
9.7 ppm (t, 1JH-P= 536 Hz) H2PO2
 , d= 4.1 ppm (d, 1JH-P= 648 Hz)
HPO3
2 ( 5:1). Elemental analysis calcd for C6H6AsNO·H2-
PO2·H2O: C 26.97, H 4.12, N 5.24%; found: C 27.50, H 3.92,
N 5.14%.
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